Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.75 |
| ▸ | MEN1 | O00255 | 7/20 | 0.75 |
| ▸ | GAA | P10253 | 3/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12417021 | 0.84 | MAPT (0.60) | MAPTKMT2AMEN1GAATDP1 | |
| SCHEMBL15600603 | 0.84 | MAPT (0.56) | MAPTKMT2AMEN1GAATDP1 | |
| SCHEMBL12417088 | 0.84 | MAPT (0.71) | MAPTKMT2AMEN1GAATDP1 | |
| SCHEMBL12417018 | 0.84 | MAPT (0.57) | MAPTKMT2AMEN1GAATDP1 | |
| SCHEMBL12417089 | 0.83 | MAPT (0.61) | MAPTKMT2AMEN1GAATDP1 | |
| SCHEMBL12417022 | 0.82 | MAPT (0.60) | MAPTKMT2AMEN1GAATDP1 | |
| SCHEMBL12416906 | 0.81 | MAPT (0.68) | MAPTKMT2AMEN1GAATDP1 | |
| SCHEMBL2137265 | 0.81 | MAPT (0.60) | MAPTKMT2AMEN1GAATDP1 | |
| SCHEMBL2137261 | 0.81 | MAPT (0.60) | MAPTKMT2AMEN1GAATDP1 | |
| SCHEMBL12417019 | 0.80 | MAPT (0.67) | MAPTKMT2AMEN1GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | MAPT 3638/4885KMT2A 2278/4885MEN1 392/4885 |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | MAPT 3638/4885KMT2A 2278/4885MEN1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.